Jieun Choe Biography and Net Worth

Insider of Certara

Ms. Choe is Certara’s Chief Strategy and Marketing Officer where she is responsible for spearheading strategic planning and all aspects of Certara’s marketing efforts, including branding, integrated marketing, market development, and market research. Previously, Jieun served as Certara’s Senior Vice President of Strategic Ventures where she developed and executed innovative, strategic initiatives for the company in collaboration with business units and key opinion leaders. She specializes in consumer insights and developing and implementing differentiated business strategies to position companies for growth.

Before joining Certara in 2016, Ms. Choe was Chief Marketing Officer at Triumph Learning and prior to that Executive Director of Marketing at Kaplan’s Precollege Division. She has also held strategic planning and product management positions at Guidant and Boston Scientific. Jieun earned her Bachelor of Arts degree in Public Policy and Economics from Stanford University and an MBA at Stanford University Graduate School of Business.

What is Jieun W. Choe's net worth?: The estimated net worth of Jieun W. Choe is at least $5.16 million as of September 17th, 2021. Ms. Choe owns 316,726 shares of Certara stock worth more than $5,162,634 as of April 26th. This net worth estimate does not reflect any other investments that Ms. Choe may own. Learn More about Jieun W. Choe's net worth.
How do I contact Jieun W. Choe?: The corporate mailing address for Ms. Choe and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on Jieun W. Choe's contact information.
Has Jieun W. Choe been buying or selling shares of Certara?: Jieun W. Choe has not been actively trading shares of Certara over the course of the past ninety days. Most recently, Jieun W. Choe sold 7,500 shares of the business's stock in a transaction on Monday, December 20th. The shares were sold at an average price of $28.00, for a transaction totalling $210,000.00. Learn More on Jieun W. Choe's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

Jieun W. Choe Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/20/2021	Sell	7,500	$28.00	$210,000.00
12/17/2021	Sell	5,000	$26.13	$130,650.00
11/19/2021	Sell	20,000	$30.30	$606,000.00
10/19/2021	Sell	20,000	$38.08	$761,600.00
9/17/2021	Sell	20,000	$35.76	$715,200.00	316,726
8/24/2021	Sell	7,500	$30.00	$225,000.00
8/19/2021	Sell	12,500	$28.34	$354,250.00	330,491

Jieun W. Choe Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $16.65

$16.21

$16.78

50 Day Range

MA: $17.72

$15.93

$19.45

2 Week Range

Now: $16.65

$11.81

$24.64

Volume

138,617 shs

Average Volume

530,943 shs

Market Capitalization

$2.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy